Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio

Myeloma Crowd Radio

×  

Follow This Show

Stay in the know about new episodes and updates.
Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

On-Demand Episodes

The coronavirus (COVID-19) is causing concern and disruption for normally healthy global citizens, but there are additional issues for multiple myeloma patients who are frequent visitors to hospitals and are often... more

Infection is a leading cause of death for multiple myeloma patients and protection against infection is key, especially during stem cell transplant. At certain points during stem cell transplant, your immune system is at an all time low until your... more

What innovation is coming in 2020 in myeloma research? Dr. Robert Orlowski of the the MD Anderson Cancer Center shares the insights learned from the recent American Society of Hematology meeting and highlights leading edge research... more

Many myeloma patients are elderly, with the average age of diagnosis being 68. If individuals are fit and active, they can typically receive the "standard of care" drugs such as stem cell transplant or triplet drug combinations. But many... more

How much does a cancer cell weigh? And why does it matter? As cancer cells die, they change their weight in a matter of hours. A new device called the Suspended Microchannel Resonator (SMR) is a new technology that can... more

Cellectar Biosciences is working on testing a radiosensitive therapy in blood cancers including multiple myeloma. Their product, CLR 131, targets the myeloma tumors by delivering a cytotoxic radioisotope, iodine-131 directly to the tumor... more

Irene Ghobrial, MD of the Dana Farber Cancer Institute and Ivan Borrello, MD of Johns Hopkins are leading the largest study on precursor myeloma conditions that will include 50,000 patients and family members. The goal of the study is... more

Why is a myeloma specialist so important? What does it take to create a new myeloma research center from scratch? William Matsui, MD recently left Johns Hopkins to do just that. Dr. Matsui is the Deputy Director of the new University... more

A new treatment called Selinexor was recently approved for highly relapsed multiple myeloma patients. Learn how experts like Dr. Paul Richardson of the Dana Farber Cancer Institute are using this new drug in their myeloma practice.... more

Immunotherapy is a major class of therapy that continues to expand in the myeloma clinic. Dr. Alexander Leshokin of Memorial Sloan Kettering Cancer Center explains the various types of immunotherapies: transplant, monoclonal... more
Show Extras

Comments

 comments